Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1133132

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Streptococcus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 March 2019 to Question 230615, and with reference to evidence demonstrating a reduction in rates of Group B Streptococcus infection in Northern Ireland since mandatory reporting of confirmed cases in babies was introduced there in March 2013, if he will make an assessment of the potential merits of making Group B Streptococcus a notifiable disease.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	266696
answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>Statutory notification of infectious diseases provides a means to alert public health officials to the occurrence of suspected or confirmed case of a given disease to direct public health action to prevent infection in others. These regulations, standards and guidance can be viewed at the following links:</p><p><a href="http://www.legislation.gov.uk/uksi/2010/659/contents/made" target="_blank">http://www.legislation.gov.uk/uksi/2010/659/contents/made</a></p><p><a href="https://www.gov.uk/guidance/notifiable-diseases-and-causative-organisms-how-to-report" target="_blank">https://www.gov.uk/guidance/notifiable-diseases-and-causative-organisms-how-to-report</a></p><p>The majority of infant Group B Streptococcus cases occur sporadically rather than through spread between individuals. As such, there are no specific public health actions recommended at present following the identification of a single case. If new evidence emerges to suggest actions should be initiated, the addition of Group B Streptococcus to the schedule of notifiable diseases will be reviewed.</p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 15:40:30 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1133133

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Northern Ireland
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the Permanent Secretary to the Northern Ireland Department of Health on that Department's working with frontline GP services to ensure that mental health support is available for teenagers immediately.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	266697
answer	answer is ministerial correction date of answer 28/06/2019 answer text <p>My Rt. hon. Friend, the Secretary of State for Health and Social Care in England, has had no such discussions with the Permanent Secretary to the Department of Health in Northern Ireland.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 28/06/2019 10:57:51 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4131 label Biography information for Jim Shannon

1133135

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dental Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to prevent tooth decay in (a) children and (b) adults.
tabling member constituency	Upper Bann
tabling member printed	David Simpson
uin	266699
answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>In England, local authorities have the lead responsibility for improving the oral health of children and adults in their local area. Further information is available at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2012/3094/pdfs/uksi_20123094_en.pdf" target="_blank">http://www.legislation.gov.uk/uksi/2012/3094/pdfs/uksi_20123094_en.pdf</a></p><p>Improving the oral health of children is a priority for Public Health England (PHE). PHE has established a Child Oral Health Improvement Programme Board, which brings together key stakeholder organisations. The board has a shared ambition that every child grows up free of tooth decay as part of getting the best start in life.</p><p>PHE established an Adult Oral Health Oversight Group, which brings together a wide range of stakeholders that have policies or areas of interest to improve the oral health of adults.</p><p>The Department is testing a new prevention focussed National Health Service dental contract which includes preventive advice and treatment based on ‘Delivering better oral health’, an evidence-based toolkit for prevention. More information about the dental contract reform programme can be found at the following link:</p><p><a href="https://www.gov.uk/government/collections/dental-contract-reform-prototypes" target="_blank">https://www.gov.uk/government/collections/dental-contract-reform-prototypes</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 12:44:49 answering member 4455 label Biography information for Seema Kennedy
tabling member	1597 label Biography information for David Simpson

1133139

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information he holds on the timescale for licensing the pill to identify breast cancer.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	266702
answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>In order for a human medicinal product to be granted a marketing authorisation, legislation requires robust data to be generated to demonstrate satisfactory quality, safety and efficacy of the proposed medicinal product and show that the benefit to risk balance is positive in the intended patient group.</p><p>Studies to evaluate the toxicity profile of a medicine using in vitro or animal models are generally performed, prior to initial safety studies (Phase I) in human volunteers. Further clinical trials (Phase II and III) are then typically performed to establish safety and efficacy in patients, prior to the submission of a marketing authorisation application.</p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for the regulation of medicines in the United Kingdom. At this time, the MHRA is not aware of any clinical trials having been planned or conducted on a product that is for oral administration to enable imaging or identification of breast cancer. Therefore, at present, it cannot provide a timeline for the licensing of such a medicine.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 13:02:56 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1133146

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Arthritis: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the provision of NHS services for people with rheumatoid arthritis.
tabling member constituency	Leeds Central
tabling member printed	Hilary Benn
uin	266693
answer	answer is ministerial correction date of answer 24/06/2019 answer text <p>The commissioning and configuration of rheumatoid arthritis services in England is a local matter. The local National Health Service is best placed to make decisions that ensure services meet the needs of resident populations in the most appropriate way. Service should be planned and delivered in line with the best available evidence, such as National Institute for Health and Care Excellence guidance.</p><p>Regarding assessment, in May 2018, a new three-year Rheumatoid and Early Inflammatory Arthritis Audit was commissioned by the Healthcare Quality Improvement Partnership. More information can be found at the following link:</p><p><a href="http://www.rheumatology.org.uk/Knowledge/Excellence/Audits" target="_blank">www.rheumatology.org.uk/Knowledge/Excellence/Audits</a></p><p>The findings of the Audit are due to be published in October 2019. However, previous Audit reports can be found at the following link:</p><p><a href="http://www.hqip.org.uk/national-programmes/a-z-of-nca/arthritis-rheumatoid-and-early-inflammatory" target="_blank">www.hqip.org.uk/national-programmes/a-z-of-nca/arthritis-rheumatoid-and-early-inflammatory</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 24/06/2019 16:55:48 answering member 4455 label Biography information for Seema Kennedy
tabling member	413 label Biography information for Hilary Benn

1133150

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Vitamin D
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has discussed the potential link between consumption of vitamin D supplements and reduced risk of developing cancer with (a) the Royal College of Nursing and (b) the General Medical Council.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	266710
answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>No such discussions have taken place.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 12:46:58 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1133151

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Migraines: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans the NHS has to introduce new drugs to tackle migraines in the next six months.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	266711
answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that provides guidance on the prevention and treatment of ill health and the promotion of good health and social care. Through its technology appraisal programme, NICE makes recommendations for the National Health Service on whether selected drugs and other treatments represent an effective use of NHS resources. NHS commissioners are legally required to fund drugs and treatments recommended through NICE’s technology appraisal programme.</p><p> </p><p>NICE is currently developing technology appraisal guidance on two drugs for the prevention of migraines; erenumab and fremanuzumab. The expected date of NICE’s final guidance is currently to be confirmed. In the absence of positive guidance from NICE, it is for commissioners to make decisions on whether to fund this treatment based on an assessment of the available evidence.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 15:48:35 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1133154

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to table 4 on page 29 of the Health Foundation's report of 18 June 2019, Investing in the NHS Long Term Plan, if he will make an assessment of the implications for his policies of the estimate that the NHS will need an additional £8 billion of investment by 2023-24 to meet the objectives in the NHS Long Term Plan.
tabling member constituency	West Ham
tabling member printed	Lyn Brown
uin	266714
answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>The National Health Service budget will increase by £33.9 billion in cash terms by 2023/24 – reflecting that the NHS is this Government’s top spending priority.</p><p> </p><p>The NHS Long Term Plan is fully costed and has been developed within the spending settlement agreed with the NHS. It sets out how the increased spending, together with stretching but achievable ambition on efficiency, should ensure the NHS can continue to deliver the world-class service we want.</p><p> </p><p>Future budgets outside the NHS England resource settlement, including those for public health, capital and workforce education and training will be set out at the forthcoming Spending Review.</p><p> </p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 27/06/2019 15:58:24 answering member 1585 label Biography information for Stephen Hammond
tabling member	1583 label Biography information for Ms Lyn Brown

1133166

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether patients whose prescription for a cannabis-based medical product is blocked by an NHS trust can appeal that decision.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	266861
answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>In line with routine clinical practice patients wishing to seek a second opinion will be supported to do so. In the first instance clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then National Health Service trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support NHS trusts in identifying a suitable NHS specialist for a second opinion. Processes may differ in Scotland, Wales and Northern Ireland.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 12:42:09 answering member 4455 label Biography information for Seema Kennedy
tabling member	4623 label Biography information for Tonia Antoniazzi

1133167

registered interest
date	19/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with (a) NHS England, (b) drug manufacturers and (c) the National Institute for Health and Care Excellence on funding for licensed cannabis-based products.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	266862
answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>The Department is in regular contact with the National Institute for Health and Care Excellence (NICE) and NHS England colleagues about a range of issues and has not met with drug manufacturers on funding of licensed cannabis-based products.</p><p>Sativex is currently the only licensed cannabis-based product available in the United Kingdom. NICE considered the clinical and cost effectiveness of Sativex in the development of its clinical guideline on the management of multiple sclerosis published in 2014. NICE was not able to recommend Sativex as a cost-effective use of NHS resources for the treatment of spasticity in people with multiple sclerosis. Sativex is not therefore routinely funded by the NHS in England for use in the treatment of multiple sclerosis, although clinicians are able to make a request for exceptional funding for individual patients who they think may benefit from treatment.</p><p>NICE has been asked to develop clinical guidelines on cannabis-based products for medicinal use and is expected to look at the clinical and cost effectiveness of treatments, including Sativex, as part of this work. This is expected to be published by October 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 12:43:17 answering member 4455 label Biography information for Seema Kennedy
tabling member	4623 label Biography information for Tonia Antoniazzi